Antibody Production and Supply
Virostat Releases New Listeria Monoclonal Antibodies
Listeriosis is a serious infection caused by the bacterium Listeria monocytogenes. This infection is contracted by eating contaminated food. The infection can lead to miscarriage, stillbirth and meningitis.
Eppendorf licenses thermal cycler technology to Bulldog Bio
September 6, 2011 – Eppendorf AG has licensed patents covering gradient technology for thermal cyclers to Bulldog Bio Inc. This worldwide license covers the popular GenePro and LifePro gradient thermal cycler models sold by Bulldog Bio.
BioBM Consulting launches LifeSciPR - a free press release site for life science companies
BioBM Consulting, a botique business and marketing consultancy serving life science tools companies, has launched LifeSciPR, a press release site specifically for companies in the life science tools and services sector.
BioBM Consulting announces distributor management & online reputation monitoring services
BioBM Consulting, a boutique business and marketing consultancy serving the life science industry, has announced the latest expansion of its life science business and marketing services with new distribution management and online reputation monitoring services.
Invention Commercialization Services for Researchers in the Life Sciences
Scientists and researchers of all sort are naturally innovative people, trained to identify problems and find solutions. This often leads to many great ideas on how to perform their own work more effectively or more efficiently, at a lower cost or with greater effectiveness.
New Toxoplasma gondii Antibodies from Virostat
Toxoplasma gondii is a common parasite that infects many animals including humans.
It is usually asymptomatic in a healthy host. However, immunocompromised individuals, including the human fetus are highly susceptible to infection from this agent; often with serious result.
Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative
COLUMBIA, Md., October 27, 2009—Precision Antibody™ has been selected as the antibody developer for a component of the National Cancer Institute (NCI)’s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.



